1. Home >
  2. M&A >
  3. Divestiture >
  4. Switzerland >
  5. Eyevance Pharmaceuticals and Hayfin Acquire Novartis AG - TOBRADEX & NATACYN

M&A Deal Summary

Eyevance Pharmaceuticals and Hayfin Acquire Novartis AG - TOBRADEX & NATACYN

On October 16, 2019, Eyevance Pharmaceuticals and Hayfin acquired medical products company Novartis AG - TOBRADEX & NATACYN from Novartis

Acquisition Highlights
  • This is Eyevance Pharmaceuticals’ 1st and Hayfin’s 1st transaction in the Medical Products sector.
  • This is Eyevance Pharmaceuticals’ 1st and Hayfin’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2019-10-16
Target Novartis AG - TOBRADEX & NATACYN
Sector Medical Products
Buyer(s) Eyevance Pharmaceuticals
Hayfin
Sellers(s) Novartis
Deal Type Divestiture

Target

Novartis AG - TOBRADEX & NATACYN

Basel, Switzerland
Novartis AG's TOBRADEX is a fixed-dose topical antibiotic and corticosteroid combination indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Novartis AG's NATACYN is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 2

Buyer

Eyevance Pharmaceuticals

Fort Worth, Texas, United States
Category Company
Founded 2017
Sector Life Science
DESCRIPTION

Eyevance Pharmaceuticals is committed to developing and commercializing innovative and impactful ophthalmic products that enable optimal vision, better quality of life, and address significant unmet medical needs. Eyevance Pharmaceuticals was founded in 2017 and is based in Fort Worth, Texas.

DEAL STATS #
Overall 2 of 2
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 2 of 2
Country: Switzerland M&A 1 of 1
Year: 2019 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-11 Focus Laboratories - FRESHKOTE

North Little Rock, Arkansas, United States

Focus Laboratories, Inc. - FRESHKOTE is a lubricant eye drop provider. FRESHKOTE® PF is designed to support the integrity of all three layers of the eye's tear film, offering dry eye patient's relief from their symptoms.

Buy -
Buyer

Hayfin

London, United Kingdom
Category Company
Founded 2009
Sector Business Services
DESCRIPTION

Hayfin is an independent investment firm that offers lending solutions to European middle-market companies and asset management services to institutional clients. Hayfin was formed in 2009 and is based in London, United Kingdom.

DEAL STATS #
Overall 4 of 5
Sector: Medical Products M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: Switzerland M&A 1 of 1
Year: 2019 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-13 Kingsland Capital Management

New York, New York, United States

Kingsland Capital Management LLC is an independent US investment manager specialising in CLOs and leveraged credit. Kingsland will operate as a wholly owned subsidiary of Hayfin following completion of the transaction, with its experienced team of eight investment professionals continuing to manage its active CLOs.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-07-02 MiMedx

Marietta, Georgia, United States

MiMedx is an advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx was formed in 2006 and is based in Marietta, Georgia.

Buy -

Seller(S) 1

SELLER

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 51.8B USD (2024)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 6 of 8
Sector: Medical Products M&A 1 of 2
Type: Divestiture M&A Deals 5 of 7
Country: Switzerland M&A 4 of 6
Year: 2019 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-05-09 Xiidra

Basel, Switzerland

XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease. Xiidra is based in Basel, Switzerland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-24 The Medicines Company

Parsippany, New Jersey, United States

The Medicines Company is a provider of solutions in acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The Medicines Company was formed in 1996 and is based in Parsippany, New Jersey. The Medicines was founded in 1996 and is based in Parsippany, New Jersey.

Buy $9.7B
Mergr

Solution for

Product

Company

Legal